Indaptus Therapeutics
INDP
17 hedge funds and large institutions have $3.51M invested in Indaptus Therapeutics in 2021 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 6 closing their positions.
80% more capital inflows, than outflows
Capital inflows: $2.38M | Capital outflows: $1.32M
2.27% more ownership
Funds ownership: 15.58% → 17.85% (+2.3%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
6% less funds holding
Funds holding: 18 → 17 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AdvisorShares Investments
Bethesda,
Maryland
|
+$1.69M |
| 2 |
Credit Suisse
Zurich,
Switzerland
|
+$191K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$148K |
| 4 |
GSA Capital Partners
London,
United Kingdom
|
+$148K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$128K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Meitav Investment House
Bene-Beraq,
Israel
|
-$566K |
| 2 |
Virtu Financial
New York
|
-$229K |
| 3 |
Millennium Management
New York
|
-$162K |
| 4 |
Renaissance Technologies
New York
|
-$128K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$113K |
INDP Hedge Fund Activity: Q1 2021 in Review
17 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q1 2021, worth a combined $3.51M — up 63% from $2.15M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of INDP and 5 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.
The largest buyer was AdvisorShares Investments, adding an estimated $1.69M. The largest seller was Meitav Investment House, cutting an estimated $566K.
- 17 institutional investors held Indaptus Therapeutics (INDP) as of Q1 2021, down from 18 in Q4 2020.
- Funds reported $3.51M of Indaptus Therapeutics stock for Q1 2021, up 63% quarter-over-quarter.
- 5 funds opened new Indaptus Therapeutics positions in Q1 2021 and 6 closed out, a net change of -1 holder.
- The largest Indaptus Therapeutics buyer in Q1 2021 was AdvisorShares Investments, an estimated $1.69M added.
- The largest Indaptus Therapeutics seller in Q1 2021 was Meitav Investment House, an estimated $566K sold.
Based on aggregated 13F filings for Q1 2021.